Llwytho...
SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
Background: The current standard of care for moderate to severe thyroid eye disease (TED) is intravenous methylprednisolone (IVMP), though alternative immunosuppressive options are emerging. In a recent randomized trial, Tocilizumab (TCZ), an anti-IL-6 receptor antibody, demonstrated improved effica...
Wedi'i Gadw mewn:
Cyhoeddwyd yn: | J Endocr Soc |
---|---|
Prif Awduron: | , , , , |
Fformat: | Artigo |
Iaith: | Inglês |
Cyhoeddwyd: |
Oxford University Press
2020
|
Pynciau: | |
Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7207507/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1316 |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|